Evolva starts Phase I Clinical Trials on EV-077
Dr. Alexandra Santana Sorensen, VP R&D of Evolva said: “We are very pleased and excited to have reached a significant Milestone by entering Phase I studies with our first drug candidate. We believe that EV-077-3201-2TBS has a very interesting potential in a number of cardiovascular and renal indications.”
EV-077-3201-2TBS is a new chemical entity, with a different mode of action from existing drugs that are being developed for cardiovascular and renal indications.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.